Article info

Original research
Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

Authors

  1. Correspondence to Dr Patrick Tan, Program in Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore; gmstanp{at}duke-nus.edu.sg; Takashi Oshima, Deparment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan; oshimat{at}kcch.jp; Akira Tsuburaya, Department of Surgery, Ozawa Hospital, Odawara, Japan; tuburayaa{at}gmail.com
View Full Text

Citation

Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, et al
Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

Publication history

  • Received January 7, 2021
  • Revised April 26, 2021
  • Accepted April 29, 2021
  • First published May 12, 2021.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.